Ideaya Biosciences, Inc.
South San Francisco, CA · Founded 2015 · CIK 0001676725 · Biotech · Private
Precision oncology therapeutics targeting specific cancer vulnerabilities through small molecule and biological drugs
ideayabio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $111M
- 2 Form D · May 2018
- 101 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 14 granted · 26 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $17,360,532 | |
| Private capital raised | Form D · SEC | $94,019,988 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1513 | SYNCANICA BIO | — | — |
| 1514 | Juvenescence | — | $115M |
| 1515 | REPLICEL LIFE SCIENCES INC. | — | $5.8M |
| 1516 | Ideaya Biosciences, Inc. | — | $111M |
| 1517 | Virscio Inc | — | — |
| 1518 | Moonwalk Biosciences | — | $110M |
| 1519 | DEGROME THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Brian DanielsDirector
- John DiekmanDirector
- Michael DillonExecutive Officer
- Jeffrey HagerExecutive Officer
- Yujiro HataDirector · Executive Officer
- Edward HuDirector
- Terry RosenDirector
- Thilo SchroederDirector
- Timothy ShannonDirector
- Tim SmithExecutive Officer
- Jeffrey SteinDirector
- Paul StoneExecutive Officer
Patents
- Treatment Of Er+ Breast Cancer Comprising Homologous Recombination Deficiency Using Parg Inhibitorapplication
- 2-OXOQUINAZOLINE Derivatives As Methionine Adenosyltransferase 2A Inhibitorsapplication
- Atropisomers Of MAT2A Inhibitorsapplication
- 2-OXOQUINAZOLINE Crystalline Formsapplication
- Cancer Treatments Using Mta-cooperative PRMT5 Inhibitors And MAT2A Inhibitorsapplication
- Thiadiazolyl Derivativesapplication
- Thiadiazolyl Derivativesgranted
- 2-OXOQUINAZOLINE Derivatives As Methionine Adenosyltransferase 2A Inhibitorsgranted
- Piperazine Substituted Indazole Compounds As Inhibitors Of Pargapplication
- Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofapplication
- Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofapplication
- Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.